Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07198373 2025-09-30

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

Not yet recruiting

40 enrolled

Lymphoid

Lymphoma, B-Cell

NCT07168291 2025-09-17

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Phase EARLY_PHASE1 Not yet recruiting

3 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05779930 2025-08-15

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Phase EARLY_PHASE1 Not yet recruiting

12 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07068906 2025-07-16

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

27 enrolled

Lymphoid

Lymphoma, B-Cell

NCT04419909 2025-07-02

Retreatment With CTL019/CTL119

Phase 1 Not yet recruiting

12 enrolled

Lymphoid

Lymphoma, B-Cell

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

20 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06767956 2025-06-04

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Not yet recruiting

30 enrolled

Lymphoid

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06956092 2025-05-02

Glofitamab

Phase 4 Not yet recruiting

40 enrolled

Lymphoid

Lymphoma, B-Cell

NCT06847529 2025-03-12

Systemic Inflammatory Markers in B-cell Neoplasm

Not yet recruiting

70 enrolled

Lymphoid

Lymphoma, B-Cell

NCT06646666 2024-11-01

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Phase 2 Not yet recruiting

35 enrolled

Lymphoid

Lymphoma, B-Cell

NCT06573099 2024-08-27

A Real-World Study on Extranodal Lymphoma

Not yet recruiting

5,000 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06062641 2023-11-07

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Phase 2 Not yet recruiting

50 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05968001 2023-08-01

Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruiting

400 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05834426 2023-06-22

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

Not yet recruiting

50 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05814848 2023-06-15

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Phase 4 Not yet recruiting

13 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

Clinical Trials

CD45BE-HSPC + CART-45 Cells

Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

REFRACT-LyMA

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

CARMEN-803

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

XP-006

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

BaseCAR-01

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Retreatment With CTL019/CTL119

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Glofitamab

Systemic Inflammatory Markers in B-cell Neoplasm

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

A Real-World Study on Extranodal Lymphoma

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Obinutuzumab in Chinese Real-world Patients With iNHL

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma